A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors

Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity

(2015) Alan Serrels et al.   CELL

A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors

(2015) Suzanne F. Jones et al.   INVESTIGATIONAL NEW DRUGS

RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas

(2013) Georgia Konstantinidou et al.   Cancer Discovery

610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma

(2012) J.C. Soria et al.   EUROPEAN JOURNAL OF CANCER

Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors

(2012) Jeffrey R. Infante et al.   JOURNAL OF CLINICAL ONCOLOGY

The Outgrowth of Micrometastases Is Enabled by the Formation of Filopodium-like Protrusions

(2012) Tsukasa Shibue et al.   Cancer Discovery

Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer

(2010) Alexander Schultze et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Targeting focal adhesion kinase signaling in tumor growth and metastasis

(2009) Joerg Schwock et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Functional inactivation of NF2/merlin in human mesothelioma

(2008) Claudio Thurneysen et al.   LUNG CANCER

Focal adhesion kinase as a regulator of cell tension in the progression of cancer

(2007) Robert W. Tilghman et al.   SEMINARS IN CANCER BIOLOGY